Coya Therapeutics
VerifiedLeveraging proprietary regulatory T cells (Tregs) and exosome platforms to address neurologic and autoimmune disorders.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$107m (Public information from Jun 2024)
Share price
$6.06 COYA
Houston Texas (HQ)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | (13 %) | 92 % | 200 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (113 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (133 %) | (240 %) | (238 %) | - |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 92 % | - | - | - |
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | $0.0 | round |
| investor | $0.0 | round | |
| N/A | $0.0 | round | |
| N/A | $0.0 | round | |
| N/A | $0.0 | round | |
* | $5.0m | Post IPO Equity | |
| Total Funding | 000k | ||